ArticleEcancermedicalscience2020
Eribulin-induced radiation recall dermatitis: a case report and brief review of the literature.
Article in Ecancermedicalscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 5 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiation recall (RR) is a fairly uncommon and unpredictable phenomenon caused by an acute inflammatory reaction in a previously irradiated area. Several antineoplastic drugs have been previously associated with RR reactions including anthracyclines and taxanes like docetaxel, paclitaxel or antimetabolites. CASE PRESENTATION: Here we report for the first time a case of a recall reaction to Eribulin mesylate, a novel chemotherapeutic compound that affects microtubule polymerisation, approved for the treatment of metastatic or locally advanced breast cancers (BCs). We present the case of a 61-year-old female BC patient originally diagnosed with bilateral BC with metastatic disease that went through several lines of chemotherapy and radiation therapy (RT); RR reaction was observed following Eribulin treatment and sequential palliative RT.
conclusionThis case report raises awareness about these fairly rare phenomena when prescribing Eribulin, or any new chemotherapeutic after RT to prevent and treat as early as possible to avoid further patient complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.